Publication Name	World Journal of Gastroenterology
Manuscript ID	80000
Country	United States

Received	2022-09-15 18:54
Peer-Review Started	2022-09-15 18:55
To Make the First Decision
Return for Revision	2023-01-03 21:47
Revised	2023-01-25 14:13
Second Decision	2023-03-08 03:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-03-14 17:36
Articles in Press	2023-03-14 17:36
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-03-21 02:16
Typeset the Manuscript	2023-04-11 06:31
Publish the Manuscript Online	2023-04-14 13:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Immunotherapy for recurrent hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Ahan Bhatt and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, 462 First Ave, BCD556, New York, NY 10016, New York, NY 10016, United States. jennifer.wu@nyulangone.org
Key Words	Immunotherapy; Hepatocellular carcinoma; Liver cancer
Core Tip	Immunotherapy has made a strong headway in the management of hepatocellular carcinoma (HCC). For patients who recur on local therapy, immunotherapy has become the standard of care treatment option for unresectable HCC. Role of immunotherapy agents is still not explored in patients who progress on prior immunotherapy. This mini-review highlights the various treatment options available in clinical practice as well as upcoming novel management strategies in recurrent HCC.
Publish Date	2023-04-14 13:45
Citation	Bhatt A, Wu J. Immunotherapy for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(15): 2261-2271
URL	https://www.wjgnet.com/1007-9327/full/v29/i15/2261.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i15.2261

Full Article (PDF)	WJG-29-2261.pdf
Full Article (Word)	WJG-29-2261.docx
Manuscript File	80000-Review-Filipodia.docx
Answering Reviewers	80000-Answering reviewers.pdf
Audio Core Tip	80000-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	80000-Conflict-of-interest statement.pdf
Copyright License Agreement	80000-Copyright license agreement.pdf
Peer-review Report	80000-Peer-review(s).pdf
Scientific Editor Work List	80000-Bing-Liu GL-2.png
Scientific Editor Work List	80000-Scientific editor work list.pdf